GlassScriptPhysician profile
April E Mela
NPI 1215274808
$3,154.44
in general payments reported to CMS, 2019-2025
31 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $906 · 2022: $607 · 2023: $577 · 2024: $363 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.41 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $297.84 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $246.29 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $218.06 | 2022-2025 | |
| Abbvie INC. | $216.09 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $181.80 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $149.33 | 2021-2025 | Farxiga |
| Pfizer INC. | $147.67 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.15 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $137.88 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $87.78 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $82.02 | 2024 | Voquezna |
| Abbott Laboratories | $72.79 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $57.64 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $46.43 | 2025 | Korlym |
| Amgen INC. | $40.11 | 2024-2025 | Otezla, Repatha, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $35.72 | 2022 | |
| Eisai INC. | $32.87 | 2021 | |
| Inspire Medical Systems, INC. | $29.87 | 2025 | Inspire |
| Daiichi Sankyo INC. | $22.95 | 2021 | |
| Medtronic, INC. | $22.34 | 2025 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $21.34 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.57 | 2023 | Rexulti |
| Genentech USA, INC. | $19.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.15 | 2022 | |
| Almatica Pharma LLC | $17.01 | 2022 | |
| Astellas Pharma US INC | $16.26 | 2021 | |
| Boston Scientific Corporation | $16.14 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $13.91 | 2022 | |
| Merck Sharp & Dohme LLC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Mela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.